Literature DB >> 33550109

Immunological characterization of chimeras of high specificity antigens from Mycobacterium tuberculosis H37Rv.

Farheen Fatma1, Dinesh K Tripathi2, Mrigank Srivastava3, Kishore K Srivastava4, Ashish Arora5.   

Abstract

Tuberculosis remains a serious global health problem. BCG is the only prophylactic TB vaccine and it shows variable protective efficacy. Chimeric protein subunit vaccines hold great potential as stand-alone vaccines or heterologous BCG prime boosters. We have designed a protein chimera, PP31, by combining Mtb ESAT-6 family antigen Rv1198 and MoCo biosynthesis family antigen Rv3111. Further, PP31 was extended by addition of latency antigen Rv1813c to yield PP43. Immunization of BALB/c mice with PP31 or PP43 with FIA adjuvant elicited strong humoral immune response. Restimulation of splenocytes of the immunized mice lead to significant proliferation of lymphocytes, secretion of cytokines IFN-γ, TNF, IL-2 of the Th1 class, IL-17A of the Th17 class, and IL-6. PP31 and PP43 also induced intracellular cytokine expression (IFN-γ, TNF, and IL-2) from both CD4+-CD44high and CD8+-CD44high T-cells. Antigen-specific IFN-γ+/IL-2+ double positive CD4+ T-cells were significantly higher in case of PP43 than PP31-immunized mice and control group. PP43 showed protection equivalent to heat-inactivated BCG in response to challenge of the immunized mice with Mtb H37Ra. Based on its immunogenicity and protective efficacy, PP43 appears to be a potential candidate for further development as a subunit vaccine against TB.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BCG; Cytokine; ESAT-6 family; FIA; Subunit vaccine; TB

Mesh:

Substances:

Year:  2021        PMID: 33550109     DOI: 10.1016/j.tube.2021.102054

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  1 in total

1.  Optimizing the Boosting Schedule of Subunit Vaccines Consisting of BCG and "Non-BCG" Antigens to Induce Long-Term Immune Memory.

Authors:  Wei Lv; Pu He; Yanlin Ma; Daquan Tan; Fei Li; Tao Xie; Jiangyuan Han; Juan Wang; Youjun Mi; Hongxia Niu; Bingdong Zhu
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.